{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"61.4","upperLimit":"82.3","value":"72.7"},{"groupId":"OG001","lowerLimit":"70.2","upperLimit":"94.3","value":"85"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Disease control rate is defined as the percentage of participants who have a confirmed CR or PR or who have SD per RECIST 1.1, as assessed by ICR","dispersionType":"95% Confidence Interval","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Final Analysis with DCO on 27Nov2024","id":"OG001","title":"NSCLC Cohort"}],"paramType":"NUMBER","populationDescription":"RES: Enrolled participants who received at least one dose of study intervention and had measurable disease at baseline by ICR.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.","title":"Disease Control Rate (DCR), Assessed by ICR","type":"SECONDARY","unitOfMeasure":"Percentage"}